KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Liabilities from Discontinued Operations (2018 - 2025)

Historic Liabilities from Discontinued Operations for Takeda Pharmaceutical (TAK) over the last 7 years, with Q4 2025 value amounting to $5.1 million.

  • Takeda Pharmaceutical's Liabilities from Discontinued Operations changed N/A to $5.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $5.1 million, marking a year-over-year change of. This contributed to the annual value of $9.8 million for FY2024, which is 81724.36% up from last year.
  • Takeda Pharmaceutical's Liabilities from Discontinued Operations amounted to $5.1 million in Q4 2025.
  • Takeda Pharmaceutical's 5-year Liabilities from Discontinued Operations high stood at $9.5 million for Q1 2024, and its period low was $1.1 million during Q1 2023.
  • For the 4-year period, Takeda Pharmaceutical's Liabilities from Discontinued Operations averaged around $6.3 million, with its median value being $5.7 million (2022).
  • Data for Takeda Pharmaceutical's Liabilities from Discontinued Operations shows a peak YoY increase of 77397.67% (in 2024) and a maximum YoY decrease of 77397.67% (in 2024) over the last 5 years.
  • Quarter analysis of 4 years shows Takeda Pharmaceutical's Liabilities from Discontinued Operations stood at $8.3 million in 2022, then plummeted by 86.89% to $1.1 million in 2023, then surged by 745.6% to $9.2 million in 2024, then plummeted by 44.67% to $5.1 million in 2025.
  • Its last three reported values are $5.1 million in Q4 2025, $4.9 million for Q3 2025, and $9.2 million during Q2 2024.